Brammer Bio, a cell and gene therapy contract development and manufacturing organization (CDMO), has launched its newly renovated cGMP manufacturing site in Cambridge, MA for gene therapy products. The 66,000 square-foot facility houses state-of-the-art equipment in cleanroom suites designed to accommodate a broad-range of gene therapy manufacturing process technologies.

“Our Cambridge site underwent a remarkable transformation,” said Mark Bamforth, president and chief executive officer of Brammer. “We converted the former biologics manufacturing space that once produced some of the first antibody-based therapies into a facility that now produces leading edge gene therapy products using a variety of manufacturing platforms.”

This comes after Brammer’s January 2017 acquisition of the site from Biogen. Today, the facility includes multiple drug substance suites able to support large-scale adherent and stirred tank production,  quality control laboratories, process development space, and more. 

The site’s launch aims to demonstrate Brammer’s end-to-end CDMO services from early phase process development through commercial manufacturing.